Allergy Therapeutics plc has announced an extension of its block admission, with an application made to the London Stock Exchange for the admission of 5,000,000 ordinary shares of 0.1 pence each in the company. These shares may be issued as a result of the exercise of share options under Allergy Therapeutics' 2013 Long Term Incentive Plan. The admission is expected to become effective on 5 October 2023, and the shares will rank pari passu with the company's existing ordinary shares. The total Block Listing will consist of 12,013,147 Ordinary Shares after this increase.

In addition, Allergy Therapeutics has provided a block listing interim review, stating that the balance of unallotted securities under the scheme from the previous return has been updated to account for 105,625 ordinary shares that were issued during the previous review period. The balance of unallotted securities under the scheme at the end of the period is 7,013,772 ordinary shares.

Allergy Therapeutics is a pharmaceutical company that specializes in the development and commercialization of allergy immunotherapy products. The company's CEO, Manuel Llobet, and CFO, Shaun Furlong, can be contacted for further information. Panmure Gordon is acting as the company's Nominated Adviser and Broker, and Consilium Strategic Communications is handling communications for the company.